G6PD and G6PD deficiency: Higher doses of tafenoquine are likely to present a higher risk of severe haemolytic events in populations with a significant prevalence of G6PD deficiency, particularly where fragile healthcare systems may result in inappropriate treatment with tafenoquine, in patients with inadequate G6PD activity.